Astrazeneca Pharma India Ltd. (BSE: 506820) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹16,078 Cr, it ranks #433 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 63 in Pharmaceuticals. At ₹6,003.00 (as of 16 Nov 2026), the share price is 36.6% below its 52-week high of ₹9,469.50 and 6.4% above its 52-week low of ₹5,640.00. The share price is down 34.3% over one year and down 22.6% over three months.
| Current Price | ₹6,003.00 |
|---|---|
| Market Cap | ₹16,078 Cr |
| BSE Code | 506820 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 85.9 |
| Return on Equity | 22.82% |
| Return on Assets | 8.33% |
| 52-Week Range | ₹5,640.00 – ₹9,469.50 |
| 1-Year Price Change | -34.3% |
| 3-Month Price Change | -22.6% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.56% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.astrazeneca.in |
| Revenue | ₹729 Cr |
|---|---|
| Net Profit | ₹62 Cr |
| Net Margin | 8.5% |
| EPS (Basic) | ₹24.93 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Astrazeneca Pharma India Ltd. reported revenue of ₹729 Cr in Q2 FY27, up 30.4% from ₹559 Cr in Q2 FY26 and up 6.8% from ₹683 Cr in Q1 FY27. It posted a net profit of ₹62 Cr for the quarter, against a net profit of ₹54 Cr in Q2 FY26 (up 15.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹480 Cr (Q4 FY25) to ₹729 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹729 Cr | ₹62 Cr | 8.5% |
| Q1 FY27 | ₹683 Cr | ₹38 Cr | 5.6% |
| Q4 FY26 | ₹579 Cr | ₹45 Cr | 7.8% |
| Q3 FY26 | ₹612 Cr | ₹33 Cr | 5.3% |
| Q2 FY26 | ₹559 Cr | ₹54 Cr | 9.7% |
| Q1 FY26 | ₹526 Cr | ₹56 Cr | 10.6% |
| Q4 FY25 | ₹480 Cr | ₹58 Cr | 12.1% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 75.00% of Astrazeneca Pharma India Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 48.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
1. Segment Adjustment-This segment manufactures, markets, and distributes pharmaceutical products; and provides clinical trial services. 2. Healthcare-0 3. Others-This segment provides clinical trial services on pharmaceutical products. 4. Unallocated Assets-0
1. Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Astrazeneca Pharma India Ltd. is trading at ₹6,003.00, with a market capitalisation of ₹16,078 Cr.
Astrazeneca Pharma India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Astrazeneca Pharma India Ltd. has a P/E of 85.9 and a return on equity of 22.82%.
Astrazeneca Pharma India Ltd. is listed on the BSE under the scrip code 506820.
Astrazeneca Pharma India Ltd.'s share price is down 34.3% over one year and down 22.6% over three months. Its 52-week range is ₹5,640.00 to ₹9,469.50.
In Q2 FY27, Astrazeneca Pharma India Ltd. reported revenue of ₹729 Cr and net profit of ₹62 Cr, with basic EPS of ₹24.93 (standalone, parsed from the company's exchange filing).
Astrazeneca Pharma India Ltd. reported revenue of ₹729 Cr in Q2 FY27, up 30.4% from ₹559 Cr in Q2 FY26 and up 6.8% from ₹683 Cr in Q1 FY27.
Promoters held 75.00% of Astrazeneca Pharma India Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.